DOCSLIB.ORG

Insulin Lispro with Continuous Subcutaneous Insulin Infusion Is Safe

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Insulin Lispro with Continuous Subcutaneous Insulin Infusion Is Safe Original Article James Thrasher, MD1; Anuj Bhargava, MD, MBA2; Tina M. Rees, PhD3; Tao Wang, PhD3; Cristina B. Guzman, MD, MBA3; Leonard C. Glass, MD3 ABSTRACT with insulin lispro. Overall, both insulin lispro and insulin aspart were well tolerated with similar AEs reported. Objective: This study provides clinical information Conclusion: Insulin lispro and insulin aspart per- regarding the use of insulin lispro versus insulin aspart in formed similarly after 16 weeks of treatment, with non- continuous subcutaneous insulin infusion (CSII) in adult inferiority for HbA1c and no significant difference in patients with type 2 diabetes mellitus (T2D). parameters measured. These findings indicate that insulin Methods: After a 2-week lead-in period, 122 subjects lispro and insulin aspart can both be used safely and effec- treated with CSII therapy were randomized to 32 weeks tively in patients with T2D using CSII. (Endocr Pract. of treatment during 2 separate 16-week treatment peri- 2015;21:247-257) ods (TPs) with crossover beginning with insulin lispro (n = 60) or insulin aspart (n = 62). Glycated hemoglobin Abbreviations: A1c (HbA1c), total daily insulin dose, and weight were AE = adverse event; BG = blood glucose; CI = confi- recorded at the end of TP1 and TP2. Adverse events (AEs) dence interval; CSII = continuous subcutaneous insulin and hypoglycemic events (overall, documented symptom- infusion; HbA1c = glycated hemoglobin A1C; LS = atic, nocturnal, or severe) were recorded throughout the least-squares; MDI = multiple daily injection; OAM = TPs. Data were analyzed using statistical methods that oral antihyperglycemic medication; NIM = noninferior- accounted for repeated measurements. ity margin; SAE = serious adverse event; T1D = type 1 Results: A total of 107 subjects completed the study; diabetes mellitus; T2D = type 2 diabetes mellitus; TP = 7 discontinued in TP1 and 8 discontinued in TP2. Insulin treatment period; TEAE = treatment-emergent adverse lispro was noninferior to insulin aspart in endpoint (weeks event; TZD = thiazolidinedione. 16 and 32) HbA1c over TP1 and TP2 combined. Total daily insulin dose, weight change, and incidence and rates of hypoglycemia were not statistically significantly differ- INTRODUCTION ent between treatments. One case of severe hypoglycemia and 1 of diabetic ketoacidosis was observed with insulin More than one-third of adults with type 2 diabetes mel- aspart. One case of severe infusion site abscess was noted litus (T2D) do not reach the American Diabetes Association goal of glycated hemoglobin A1c (HbA1c) less than 7% (1,2). The use of continuous subcutaneous insulin infusion (CSII) in T2D, although currently less common than in type 1 diabetes (T1D), allows for tight glucose control and has been shown to result in either similar or improved HbA1c Submitted for publication May 29, 2014 Accepted for publication September 15, 2014 values versus multiple daily injection (MDI), no reported From the 1Medical Investigations, Inc, Little Rock, Arkansas; 2Iowa Diabetes increase in hypoglycemia, and improved patient satisfac- and Endocrinology Research Center, Des Moines, Iowa; 3Eli Lilly and tion (3,4). As the number of patients with T2D continues to Company, Lilly Diabetes, Indianapolis, Indiana. Address correspondence to Tina Rees, Eli Lilly and Company; Lilly increase, so does the use of CSII in this population; there- Diabetes, Lilly Corporate Center, Indianapolis, IN 46285. fore, it is valuable to gain more clinical information on the E-mail: [email protected]. effects of different analog insulins in these patients. Published as a Rapid Electronic Article in Press at http://www.endocrine practice.org on November 4, 2014. DOI: 10.4158/EP14242.OR This study compared the efficacy and safety of 2 rapid- To purchase reprints of this article, please visit: www.aace.com/reprints. acting analogs, insulin lispro and insulin aspart, in a T2D Copyright © 2015 AACE. population already using CSII. The primary objective was ENDOCRINE PRACTICE Vol 21 No. 3 March 2015 247 248 to demonstrate that CSII with lispro in patients with T2D Following a screening period of up to 2 weeks, eli- was noninferior (noninferiority margin [NIM] 0.4%) to gible subjects were randomly assigned (1:1) by an inter- CSII with insulin aspart as measured by HbA1c at the end active voice response system to either insulin lispro or of each treatment period (TP). A 0.4% NIM was chosen for insulin aspart for 16 weeks (TP1) followed by crossover this study because it is comparable to other similar stud- to the other treatment for an additional 16 weeks (TP2) for ies (5-7). The secondary objectives of the study were to a total TP of 32 weeks. Subjects were stratified based on compare CSII use of insulin lispro with insulin aspart with screening HbA1c value (≤8% and >8%) and thiazolidin- respect to total daily insulin dose (U/day and U/kg/day) edione (TZD) use (yes or no). Subjects in a crossover study at endpoints of the 2 TPs (i.e., week 16 for TP1 and week serve as their own control, which can efficiently reduce the 32 for TP2), rate and frequency of hypoglycemic events, impact of the between-subject variability (11) and baseline weight change, and adverse events (AEs) over each of the characteristics to the analysis. Because HbA1c measures 2 TPs. the previous 8 to 12 weeks of glycemic control (12) and is heavily weighted to the 4 weeks preceding the measure- METHODS ment (13), and because insulin lispro and insulin aspart have half-lives measured in minutes (14-16), a 16-week Study Patients TP was selected to minimize the risk of carryover effect Male or female subjects with T2D (8) who were 18 and to ensure that the endpoint measurement (32 weeks) to 85 years of age at screening, treated with CSII therapy in TP2 reflected glycemic control influenced only by the using a rapid-acting analog for at least 6 months before second insulin treatment. Subjects, investigators, and all screening, and had an HbA1c ≤9.0% at screening were other personnel involved in the conduct of the study were included. Subjects taking oral antihyperglycemic medica- blinded to the individual treatment assignments for the tions (OAMs) were required to be on a stable dose for at study duration. least 3 months prior to screening. Clear solutions of insulin lispro (Humalog®, 100 U/ Subjects with more than 1 episode of severe hypo- mL, Eli Lilly and Company, Indianapolis, IN) and insu- glycemia (defined as requiring third-party assistance) lin aspart (NovoLog®, 100 U/mL, Novo Nordisk, A/S, within 6 months before study entry, who had severe insulin Bagsværd, Denmark) were provided separately in 10-mL resistance (required >2 U/kg/day), or who were taking or covered vials to mask insulin type and were used to fill the took OAMs not approved in the U.S. for use with insu- pump reservoirs. Subjects administered the insulin by CSII lin or injectable noninsulin antihyperglycemic medica- in 1 of 2 sequences that were each 16 weeks long. Subjects tions within 3 months of screening were excluded from the used their own insulin pump systems during the study, irre- study. Other exclusion criteria included having a history of spective of brand, and continued with their existing insulin hypoglycemia unawareness (routinely asymptomatic with dosing regimens (basal rates, meal boluses [with/without a blood glucose [BG] level <45 mg/dL); having severe carbohydrate counting algorithms], and correction boluses). infection or an abscess at the infusion site(s) up to 1 year Subjects already using a continuous glucose monitor prior to screening; having a history of lipohypertrophy or were permitted to continue as long as they maintained its lipoatrophy at the infusion site(s); or having multiple, clin- use for the study duration. Subjects were all given the same ically significant, pump-related occlusions, as judged by an model of BG meter, a diary to record BG measurements investigator. and hypoglycemic events for review by site personnel, and other diabetes supplies. Qualified medical staff reviewed Study Design and with the subjects the need to maintain their physical activi- Treatments Administered ties, BG monitoring, and provided training on the BG meter This was a phase 3b, multi-center, randomized, and study diary entry. Signs and symptoms of hypo- and double-blind, active comparator, 2 period (16 weeks hyperglycemia and appropriate treatment were reviewed each), 2-sequence, 32-week crossover trial comparing with subjects. insulin lispro with insulin aspart in subjects with T2D At randomization (week 0) and the crossover visit using CSII. The study was registered with clinicaltrials. (week 16), subjects changed their infusion site and tubing gov (NCT01474538) and was conducted across 12 sites (if using a pump with tubing) and filled a new reservoir in the United States in accordance with the principles with the investigational product under the observation of of the Declaration of Helsinki (9) and the International study site staff. At the last study visit (week 32), subjects Conference on Harmonisation Good Clinical Practices changed their infusion sites and filled the new reservoirs E6 Guideline (10). The protocol and informed consent with their poststudy insulin as designated by their investi- form were approved by an ethical review board. Informed gator or physician. All other reservoir and tubing changes consent was obtained from each patient or their legal were done according to standard practice and the investiga- representative. tors’ recommendations. 249 Subject characteristics and demographic variables incidence of AEs and hypoglycemic events were analyzed were obtained at screening, and baseline hypoglyce- using the Prescott test (17). Incidence of hypoglycemic mia was captured between screening and randomization. episodes was summarized for the individual TPs. The inci- HbA1c was collected at screening, randomization (week dence of hypoglycemic episodes (total, severe, nocturnal, 0), the end of each TP (weeks 16 and 32), and, if applicable, and documented symptomatic) was reported by treatment at early termination.
Load more

Recommended publications
  • Treatment of Diabetes Mellitus
    TREATMENT OF DIABETES MELLITUS DIABETES is a condition that affects how the body makes energy from food. Food is broken down into sugar (glucose) in the body and released into the blood. When the blood sugar level rises after a meal, insulin responds to let the sugar into the cells to be used as energy. In diabetes, the body either does not make enough insulin or it stops responding to insulin as well as it should. This results in sugar staying in the blood and leads to serious health problems over time. DIAGNOSIS OF DIABETES1 • A1C Test: Lab test measuring average blood sugar over past two to three months • Fasting Blood Sugar Test: Lab test measuring blood sugar after eight hours of no food or drink • Oral Glucose Tolerance Test (OGTT): Measures blood sugar before and two hours after drinking a specific sugary liquid • Random Blood Sugar Test: Measures blood sugar at a moment in time, without any kind of preparation (like fasting) FASTING BLOOD ORAL GLUCOSE TOLERANCE RANDOM BLOOD RESULT A1C TEST SUGAR TEST TEST SUGAR TEST Diabetes ≥ 6.5% ≥126 mg/dL ≥ 200 mg/dL ≥ 200 mg/dL Prediabetes 5.7 – 6.4% 100 – 125 mg/dL 140 – 199 mg/dL N/A Normal < 5.7% ≤99 mg/dL < 140 mg/dL N/A NON-DRUG TREATMENTS2 THERAPY COST WHAT TO EXPECT Diet (Mediterranean diet) and exercise (30 minutes a day, five days a week of moderate- Weight loss $-$$ intensity exercise); 7% weight loss decreases risk of diabetes3 Psychological intervention $$-$$$ Psychotherapy may reduce diabetic distress and improve glycemic control4,5 nationalcooperativerx.com PRESCRIPTION TREATMENTS
    [Show full text]
  • Januvia (Sitagliptin) Tablets
    CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for: APPLICATION NUMBER: NDA 021995/S-013 Trade Name: JANUVIA Generic Name: Sitagliptin Sponsor: Merck & Co., Inc. Approval Date: 12/28/2009 Indications: JANUVIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: NDA 021995/S-013 CONTENTS Reviews / Information Included in this NDA Review. Approval Letter X Other Action Letters X Labeling X Summary Review Officer/Employee List Office Director Memo Cross Discipline Team Leader Review Medical Review(s) X Chemistry Review(s) Environmental Assessment Pharmacology Review(s) X Statistical Review(s) Microbiology Review(s) Clinical Pharmacology/Biopharmaceutics Review(s) Risk Assessment and Risk Mitigation Review(s) X Proprietary Name Review(s) Other Review(s) X Administrative/Correspondence Document(s) X CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: NDA 021995/S-013 APPROVAL LETTER DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 021995/S-013 SUPPLEMENT APPROVAL Merck & Co., Inc. Attention: Richard J. Swanson, Ph.D. Director, Regulatory Affairs P.O. Box 1000, UG2C-50 North Wales, PA 19454-1099 Dear Dr. Swanson: Please refer to your supplemental new drug application (S-013) dated and received March 5, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Januvia (sitagliptin) tablets. We also refer to your supplemental new drug application (b) (4) dated and received November 13, 2009. Your submission of November 13, 2009, also constitutes a complete response to our October 16, 2009, action letter for supplemental application S-013.
    [Show full text]
  • Pharmacokinetics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 Inhibitor
    Available online a t www.derpharmachemica.com ISSN 0975-413X Der Pharma Chemica, 2016, 8(12):292-295 CODEN (USA): PCHHAX (http://derpharmachemica.com/archive.html) Mini-review: Pharmacokinetics of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor Nermeen Ashoush a,b aClinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, British University in Egypt, El- Sherouk city, Cairo 11837, Egypt. bHead of Health Economics Unit, Center for Drug Research and Development (CDRD), Faculty of Pharmacy, British University in Egypt, El-Sherouk city, Cairo 11837, Egypt. _____________________________________________________________________________________________ ABSTRACT The dipeptidyl peptidase-4 (DPP-4) inhibitors are novel oral hypoglycemic drugs which have been in clinical use for the past 10 years. The drugs are safe, weight neutral and widely prescribed. There are currently many gliptins approved by FDA, namely sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin with several more in advanced stages of development. The gliptins may possess cardiovascular protective effects and their administration may promote β-cell survival; claims currently being evaluated in clinical and preclinical studies. The gliptins are an optional second-line therapy after metformin; they are generally well tolerated with low risk of hypoglycemia. The various compounds differ with respect to their pharmacokinetic properties; however, their clinical efficacy appears to be similar. The clinical differences between the various compounds
    [Show full text]
  • TREATMENT of TYPE 2 DIABETES with BIPHASIC INSULIN ANALOGUES *Ali A
    TREATMENT OF TYPE 2 DIABETES WITH BIPHASIC INSULIN ANALOGUES *Ali A. Rizvi Professor of Medicine, Department of Medicine and Director, Division of Endocrinology, University of South Carolina School of Medicine, Columbia, South Carolina, USA *Correspondence to [email protected] Disclosure: The author has received grant support, as principal investigator at the University of South Carolina site, from the National Institutes of Health (NIH) for the SPRINT Trial (Contract Number: HHSN268200900040C, ClinicalTrials.gov Identifier: NCT01206062). The contents of this paper do not necessarily represent the views of the NIH. Received: 29.03.16 Accepted: 09.09.16 Citation: EMJ Diabet. 2016;4[1]:74-83. ABSTRACT The majority of patients with Type 2 diabetes require insulin therapy for treating hyperglycaemia. There are several regimens available for insulin initiation and maintenance. Insulin analogues have been developed to mimic normal physiology as closely as possible. Biphasic analogues can target both fasting and postprandial hyperglycaemia, with the added advantage of being premixed and thus convenient for the patient. A practical and feasible option is to initiate insulin with one or more biphasic preparations at mealtimes, thus providing both basal and prandial coverage. Individual titration of dose and frequency of daily injections with biphasic insulin preparations has the potential for improving glycaemic control with a high degree of patient acceptance. Drawbacks include a more rigid regimen, a relative lack of flexibility, and a somewhat higher degree of glycaemic variability and hypoglycaemia when compared to multiple daily basal-bolus injections. Awareness of the advantages and limitations of biphasic insulin analogues can assist clinicians in their appropriate use for the treatment of patients with Type 2 diabetes.
    [Show full text]
  • Sitagliptin: a New Class of Oral Drug for Type 2 Diabetes
    JK SCIENCE DRUG REVIEW Sitagliptin: a New Class of Oral Drug for Type 2 Diabetes Dinesh K. Badyal, Jasleen Kaur Introduction Pharmacokinetics Type 2 diabetes is the most common form of the Bioavailability of sitagliptin is approximately 87%. Half- disease, accounting for about 90% to 95 % of all diagnosed life is between 8-14 hours. It is 38% bound to plasma cases of diabetes. In type 2 diabetes, the body does not proteins. It undergoes limited metabolism via CYP3A4 produce enough insulin or the cells ignore the insulin. and CYP2C8. Elimination is mainly through urine (5, 6). Over time, high blood sugar levels can increase the risk Clinical Use for serious complications, including heart disease, In October 2006, the U.S. Food and Drug blindness, nerve damage and kidney damage (1). Any Administration (FDA) approved sitagliptin as new oral hypoglycemic drug that can increase the control monotherapy and as add-on therapy to either of two other of blood glucose with fewer adverse effects in patients types of oral diabetes medications, metformin or with diabetes may be welcomed. Sitagliptin is the first thiazolidinediones to improve blood glucose control in and only prescription medication in a new class of oral patients with type 2 diabetes when diet and exercise are antihyperglycemic agents, which enhance the body's own not enough (5). In March, 2007 it was approved in ability to lower blood glucose when it is elevated (2). European Union. Sitagliptin is currently approved in 42 Mechanism of Action countries (7). The recommended dose of sitagliptin is Sitagliptin prolongs the activity of proteins that increase 100 mg once daily.
    [Show full text]
  • Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly
    2106 Diabetes Care Volume 38, November 2015 fi Wayne H.-H. Sheu,1 Ira Gantz,2 Safety and Ef cacy of Omarigliptin Menghui Chen,2 Shailaja Suryawanshi,2 Arpana Mirza,2 Barry J. Goldstein,2 (MK-3102), a Novel Once-Weekly Keith D. Kaufman,2 and Samuel S. Engel2 DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes Diabetes Care 2015;38:2106–2114 | DOI: 10.2337/dc15-0109 OBJECTIVE This study was conducted to determine the optimal dose of omarigliptin, a once- weekly (q.w.) dipeptidyl peptidase IV (DPP-4) inhibitor, for the treatment of patients with type 2 diabetes and evaluate the long-term safety of that dose. RESEARCH DESIGN AND METHODS In a multicenter, double-blind, 12-week, dose-range finding study, 685 oral antihy- perglycemic agent-na¨ıve or washed-out subjects with type 2 diabetes were random- ized to one of five once-weekly doses of omarigliptin (0.25 mg, 1 mg, 3 mg, 10 mg, or 25 mg) or placebo. The primary efficacy end point was change from baseline in HbA1c, and secondary end points were 2-h postmeal glucose (PMG) and fasting plasma glucose (FPG). Analysis included all patients who received at least one dose of the study medication. Subjects who completed the base study were eligible to enter a 66-week extension study. RESULTS Once-weekly treatment for 12 weeks with omarigliptin provided dose-related reduc- 1Division of Endocrinology and Metabolism, De- partment of Internal Medicine, Taichung Veterans EMERGING TECHNOLOGIES AND THERAPEUTICS tions in HbA , 2-h PMG, and FPG.
    [Show full text]
  • Januvia (Sitagliptin)
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2021 P 3084-7 Program Step Therapy – Diabetes Medications- DPP4 Inhibitors Medication Januvia (sitagliptin)*, Janumet (sitagliptin/metformin immediate- release)*, Janumet XR (sitagliptin/metformin extended-release)* P&T Approval Date 10/2016, 10/2017, 1/2018, 10/2019, 4/2020, 5/2020, 5/2021 Effective Date 8/1/2021; Oxford only: 8/1/2021 1. Background: Januvia (sitagliptin)* is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Janumet (sitagliptin/metformin)* and Janumet XR (sitagliptin/metformin extended-release)* are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin/metformin extended-release is appropriate. 2. Coverage Criteriaa: A. Januvia* will be approved based on the following criterion: 1. History of a three month trial resulting in a therapeutic failure, contraindication (e.g. risk factors for heart failure), or intolerance to both of the following (list reason for therapeutic failure, contraindication, or intolerance)b: a. Tradjenta (linagliptin) -AND- b. One of the following: (1) Nesina (alogliptin) (2) Onglyza (saxagliptin) Authorization will be issued for 12 months B. Janumet* and Janumet XR* will be approved based on the following criterion: 1. History of a three month trial resulting in a therapeutic failure, contraindication (e.g. risk factors for heart failure), or intolerance to all of the following (list reason for therapeutic failure, contraindication, or intolerance)b: a. Jentadueto (linagliptin/metformin immediate-release)/Jentadueto XR (linagliptin/metformin extended-release) -AND- b.
    [Show full text]
  • Combination Use of Insulin and Incretins in Type 2 Diabetes
    Canadian Agency for Agence canadienne Drugs and Technologies des médicaments et des in Health technologies de la santé CADTH Optimal Use Report Volume 3, Issue 1C Combination Use of Insulin and July 2013 Incretins in Type 2 Diabetes Supporting Informed Decisions This report is prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). The report contains a comprehensive review of the existing public literature, studies, materials, and other information and documentation (collectively the “source documentation”) available to CADTH at the time of report preparation. The information in this report is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this report should not be used as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process, nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of this document to ensure that its contents are accurate, complete, and up to date as of the date of publication, CADTH does not make any guarantee to that effect. CADTH is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in the source documentation. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the information in this document or in any of the source documentation.
    [Show full text]
  • Linagliptin (Tradjenta) for the Treatment of Diabetes Mellitus KAREN WHALEN, Pharmd, BCPS, CDE, and KAREN R
    STEPS New Drug Reviews Linagliptin (Tradjenta) for the Treatment of Diabetes Mellitus KAREN WHALEN, PharmD, BCPS, CDE, and KAREN R. SANDO, PharmD, CDE University of Florida College of Pharmacy, Gainesville, Florida STEPS new drug reviews Linagliptin (Tradjenta) is a dipeptidyl-peptidase-4 (DPP-4) inhibitor labeled for the treat- cover Safety, Tolerability, ment of type 2 diabetes mellitus. Similar to sitagliptin (Januvia) and saxagliptin (Onglyza), Effectiveness, Price, and Simplicity. Each indepen- linagliptin delays the breakdown of endogenous incretin hormones such as glucagon-like dent review is provided peptide 1 and glucose-dependent insulinotropic polypeptide. These hormones, when secreted by authors who have no in response to food intake, stimulate postmeal insulin secretion, inhibit glucagon release, financial association with improve satiety, and slow gastric emptying.1,2 Linagliptin can be used alone or in combination the drug manufacturer. with metformin (Glucophage), sulfonylureas, pioglitazone (Actos), or insulin. The series coordinator for AFP is Allen F. Shaugh- nessy, PharmD, Tufts Drug Dosage Dose form Cost* University Family Medicine Residency Program at Linagliptin (Tradjenta) 5 mg daily 5-mg tablet $254 for 30 tablets Cambridge Health Alli- ance, Malden, Mass. *—Estimated retail price of one month’s treatment based on information obtained at http://www.goodrx.com A collection of STEPS pub- (accessed October 1, 2012). lished in AFP is available at http://www.aafp.org/ afp/steps. SAFETY control should be used in patients receiving Few severe adverse effects have been associ- strong inducers of cytochrome P450 3A4 ated with linagliptin. When used alone or or P-glycoprotein, such as rifampin. Lina- with metformin or pioglitazone, linagliptin gliptin is a U.S.
    [Show full text]
  • A Randomized Controlled Trial of Liraglutide Versus
    Therapeutics The Journal of Clinical Pharmacology A Randomized Controlled Trial of Liraglutide 2015, XX(XX) 1–8 © 2015, The American College of Clinical Pharmacology Versus Insulin Detemir Plus Sitagliptin: Effective DOI: 10.1002/jcph.483 Switch From Intensive Insulin Therapy to the Once-Daily Injection in Patients With Well-Controlled Type 2 Diabetes Yuichiro Inoue, MD1, Akinobu Nakamura, MD, PhD1,2, Yoshinobu Kondo, MD1,3, Kumiko Hamano, MD4, Shinobu Satoh, MD, PhD3, and Yasuo Terauchi, MD, PhD1 Abstract This study aimed to compare the efficacy and safety of liraglutide versus insulin detemir plus sitagliptin in Japanese patients with type 2 diabetes treated with a basal-bolus insulin regimen. In this multicenter, open-label trial, 90 patients whose diabetes had been controlled well or moderately (glycated hemoglobin [HbA1c] 7.3%) with basal-bolus insulin regimen were randomly assigned to a liraglutide group or a detemir group and were followed up for 24 weeks. The primary end point was HbA1c change from baseline to 24 weeks. Of the 90 enrolled patients, 82 completed this trial. At 24 weeks, the mean changes in HbA1c from baseline were 0.1% Æ 0.9% versus 0.3% Æ 0.8% in the liraglutide versus detemir groups, respectively (P ¼ .46). The “overall” satisfaction score for the Diabetes Treatment Satisfaction Questionnaire changed from 25.2 Æ 7.4 to 29.9 Æ 5.3 (P < .001) and from 26.4 Æ 6.1 to 28.3 Æ 6.4 (P ¼ .12) in the liraglutide and detemir groups, respectively. Although the mean change difference in HbA1c between both groups was not significant, switching from a basal-bolus insulin regimen to liraglutide once daily improved patient satisfaction levels without loss of glycemic control.
    [Show full text]
  • JANUMET® XR (JAN-You-Met XR) (Sitagliptin and Metformin
    Medication Guide JANUMET® XR (JAN-you-met XR) (sitagliptin and metformin hydrochloride extended-release) tablets, for oral use Read this Medication Guide carefully before you start taking JANUMET XR and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. If you have any questions about JANUMET XR, ask your doctor or pharmacist. What is the most important information I should know about JANUMET XR? JANUMET XR can cause serious side effects, including: 1. Lactic Acidosis. Metformin, one of the medicines in JANUMET XR, can cause a rare but serious condition called lactic acidosis (a buildup of an acid in the blood) that can cause death. Lactic acidosis is a medical emergency and must be treated in the hospital. Stop taking JANUMET XR and call your doctor right away if you have any of the following symptoms, which could be signs of lactic acidosis: you feel cold in your hands or feet you feel dizzy or lightheaded you have a slow or irregular heartbeat you feel very weak or tired you have unusual (not normal) muscle pain you have trouble breathing you feel sleepy or drowsy you have stomach pains, nausea or vomiting Most people who have had lactic acidosis with metformin have other things that, combined with the metformin, led to the lactic acidosis. Tell your doctor if you have any of the following, because you have a higher chance for getting lactic acidosis with JANUMET XR if you: have severe kidney problems or your kidneys are affected by certain x-ray tests that use injectable dye have liver problems drink alcohol very often, or drink a lot of alcohol in short-term "binge" drinking get dehydrated (lose a large amount of body fluids).
    [Show full text]
  • Is the Use of DPP-4 Inhibitors Associated with an Increased Risk for Heart Failure?
    S210 Diabetes Care Volume 39, Supplement 2, August 2016 Is the Use of DPP-4 Inhibitors Guntram Schernthaner,1 Avivit Cahn,2 and Itamar Raz2 RECENT OUTCOME STUDIES Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS Diabetes Care 2016;39(Suppl. 2):S210–S218 | DOI: 10.2337/dcS15-3009 About 40 years ago, the Framingham study first documented that the risk for heart failure (HF) in patients with diabetes was about twofold higher in men and fivefold in women compared with individuals without diabetes (1). The UK Prospective Di- abetes Study (UKPDS) reported that the incidence of hospital admission for HF was similar to that of nonfatal myocardial infarction and nonfatal stroke (2). A more recent 6-year follow-up study of 65,619 patients with type 2 diabetes treated with insulin reported that the hospital admission rate due to HF (243 of 10,000) was higher than that due to myocardial infarction (97 of 10,000) or stroke (151 of 10,000) (3). The pathogenesis of HF in diabetes is multifactorial but can largely be attributed to four key factors: coronary artery disease (CAD), hypertension, diabetic cardio- myopathy, and extracellular fluid volume expansion (4,5). Remarkably, type 2 di- abetes itself is a recognized risk factor for HF, independent of CAD and hypertension (4), suggesting that glycemic control may influence the development of HF. Hyper- glycemia can exert deleterious effects on the myocardium and has been shown to increase oxidative stress, promote accumulation of advanced glycation end prod- ucts, and cause interstitial fibrosis (6).
    [Show full text]